GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

RGI performs companion diagnostic tests and other related activities for GSK’s immunotherapies and oncology pipeline candidates.